<SEC-DOCUMENT>0001062822-22-000030.txt : 20220630
<SEC-HEADER>0001062822-22-000030.hdr.sgml : 20220630
<ACCEPTANCE-DATETIME>20220630125230
ACCESSION NUMBER:		0001062822-22-000030
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220629
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20220630
DATE AS OF CHANGE:		20220630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		221057218

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrx-20220629.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:7f89d13d-bd55-4120-abc6-81eefc01febb,g:126522bb-f532-4f89-a56b-06c2467ad2f3,d:86fafe9698df400793c90e565a27b700--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20220629</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF80L2ZyYWc6NTJiZjNiNmRjM2EwNGNkYWI0ZDRlZjU3MjAxYzRjZGIvdGFibGU6YTFmZTk1MDBlZTU2NDVjZWI3ZGFkNjVkNzI2NzZlMDIvdGFibGVyYW5nZTphMWZlOTUwMGVlNTY0NWNlYjdkYWQ2NWQ3MjY3NmUwMl8wLTEtMS0xLTI4NDM2_b003f9b1-65cc-4e66-be97-dc579ecd1f1c">0001062822</ix:nonNumeric><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF80L2ZyYWc6NTJiZjNiNmRjM2EwNGNkYWI0ZDRlZjU3MjAxYzRjZGIvdGFibGU6YTFmZTk1MDBlZTU2NDVjZWI3ZGFkNjVkNzI2NzZlMDIvdGFibGVyYW5nZTphMWZlOTUwMGVlNTY0NWNlYjdkYWQ2NWQ3MjY3NmUwMl8xLTEtMS0xLTI4NDM2_577c79da-866c-42c7-afeb-275fce7c1969">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20220629.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i86fafe9698df400793c90e565a27b700_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNzAx_7ca3b16b-b842-465d-bd13-301673a0c408">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8yNjU_d6bbfc79-97d5-4bc7-b2d8-08f7f9c3a11d">June 29, 2022</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk0_14fd1dd3-ea88-49c2-aac1-42e41265cdae">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:32.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6MjRjNjZiZTRhMzI5NGQwY2E3Y2I5NDNiNDBmYmE3NzQvdGFibGVyYW5nZToyNGM2NmJlNGEzMjk0ZDBjYTdjYjk0M2I0MGZiYTc3NF8wLTAtMS0xLTI4NDM2_58e24a9a-1d33-48b7-a8c7-3ed0562cb747">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6MjRjNjZiZTRhMzI5NGQwY2E3Y2I5NDNiNDBmYmE3NzQvdGFibGVyYW5nZToyNGM2NmJlNGEzMjk0ZDBjYTdjYjk0M2I0MGZiYTc3NF8wLTEtMS0xLTI4NDM2_3366901e-84f6-48ab-85eb-4aa8e6bc112e">000-30111</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6MjRjNjZiZTRhMzI5NGQwY2E3Y2I5NDNiNDBmYmE3NzQvdGFibGVyYW5nZToyNGM2NmJlNGEzMjk0ZDBjYTdjYjk0M2I0MGZiYTc3NF8wLTItMS0xLTI4NDM2_ed83d2ad-f35f-4c8f-9ea8-2e86bf8662ed">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjg4_8f86efce-d665-439c-84c8-3f0bd141fcfd">2445 Technology Forest Blvd., 11th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNzAw_03b9f13c-fd6c-4a12-991a-35a18d72968f">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk1_6fc75b76-31c3-4294-9237-f88b684d76c6">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl80MjA_2e8f6787-3d8d-42ef-8f0a-faff555a5f33">77381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices and Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl80Nzk_a059fc45-5a64-4d2c-a414-e6c08dad9438">281</ix:nonNumeric>) <ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjg5_9028f1c3-9661-4144-bec3-e8c057c85fdb">863-3000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:34.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6NzkzYzljYTJkMTc2NGM4MjljYWZiNGE0MTM0YWY5MWUvdGFibGVyYW5nZTo3OTNjOWNhMmQxNzY0YzgyOWNhZmI0YTQxMzRhZjkxZV8xLTAtMS0xLTI4NDM2_4cf0759b-9924-4aa3-8402-9ca14b20a188">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6NzkzYzljYTJkMTc2NGM4MjljYWZiNGE0MTM0YWY5MWUvdGFibGVyYW5nZTo3OTNjOWNhMmQxNzY0YzgyOWNhZmI0YTQxMzRhZjkxZV8xLTEtMS0xLTI4NDM2_3dd76deb-e45c-4204-8df1-7d548457800d">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6NzkzYzljYTJkMTc2NGM4MjljYWZiNGE0MTM0YWY5MWUvdGFibGVyYW5nZTo3OTNjOWNhMmQxNzY0YzgyOWNhZmI0YTQxMzRhZjkxZV8xLTItMS0xLTI4NDM2_14add6c8-b186-44be-b064-67ead65c2b46">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjkw_bd8eb20b-1152-4dd1-85e4-2c4899d04078">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17&#160;CFR&#160;230.425)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk2_e94743a3-085a-4bc6-abf0-bcb8e0e79416">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17&#160;CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk3_3fcaa6cd-b422-4272-aaee-4cc1ff4ebc0d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&#160;CFR 240.14d-2(b))</span></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjky_2c5c0b1b-8038-4d41-a0fb-d53b6e26b337">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&#160;CFR&#160;240.13e-4(c))</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk5_1650b037-1fcc-48a6-867c-c7905ef6e5ec">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:29.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i86fafe9698df400793c90e565a27b700_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 8.01&#160;&#160;&#160;&#160;Other Events</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 29, 2022, we announced top-line results of RELIEF-DPN-1, our Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.  LX9211 achieved the primary endpoint of the study, demonstrating a statistically significant reduction in average daily pain score (ADPS) at week 6 compared to placebo in the low dose arm with results that plateaued in the high dose arm.  Separation from placebo was seen by week 1 in both dose arms, and the effect was consistent across age, sex, concurrent use of medications for painful diabetic neuropathy, and baseline pain score. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Patient reported outcomes (global impression of change) were improved in patients treated with LX9211 compared to placebo.  Adverse events were more frequent in the LX9211 treatment arms and at the higher dose, with the most common being dizziness, headache and nausea.  Nearly all adverse events were reported as mild or moderate. There were no drug-related serious adverse events reported in the study.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">RELIEF-DPN-1 is a Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy, safety and pharmacokinetics of LX9211 in the treatment of painful diabetic neuropathy, also referred to as diabetic peripheral neuropathic pain.  The study enrolled 319 patients at approximately 40 U.S. clinical sites, evaluating three treatment groups receiving placebo or one of two dosing regimens of LX9211 (an initial dose of 100 mg followed by once-daily doses of 10 mg or an initial dose of 200 mg followed by once-daily doses of 20 mg). The primary efficacy endpoint under evaluation was the change from baseline to week 6 in ADPS, based on the 11-point numerical rating scale.  The results of the study on the primary endpoint showed a reduction from baseline in ADPS of 1.39 points (p=0.007 versus placebo) in the low dose arm and 1.27 points (p=0.030 versus placebo) in the high dose arm, compared to 0.72 in the placebo arm.  Under the statistical analysis plan for the study, a p-value of less than 0.028 was considered statistically significant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 29, 2022, we issu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ed a press release announcing the top-line results of RELIEF-DPN-1.  A copy of the press release is attached to this current report on Form&#160;8-K as Exhibit&#160;99.1.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i86fafe9698df400793c90e565a27b700_10"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:13.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressrelease06-29x2022.htm">Press Release of Lexicon Pharmaceuticals, Inc. dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressrelease06-29x2022.htm">June </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressrelease06-29x2022.htm">29</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pressrelease06-29x2022.htm">, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EX-104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i86fafe9698df400793c90e565a27b700_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:50.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   June 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Brian T. Crum</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Senior Vice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">President and General Counsel</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease06-29x2022.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9dd94be23968471e80b93c37c659c4cd_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LEXICON ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY OF LX9211 IN PAINFUL DIABETIC NEUROPATHY</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Conference Call and Webcast at 8&#58;00 a.m. Eastern Time June 30, 2022</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">The Woodlands, Texas, June 29, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> - </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon Pharmaceuticals, Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. (Nasdaq&#58; LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LX9211 achieved the primary endpoint of the study, demonstrating a statistically significant reduction in average daily pain score (ADPS) at week 6 compared to placebo in the low dose arm with results that plateaued in the high dose arm.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Separation from placebo was seen by week 1 in both dose arms, and the effect was consistent across age, sex, concurrent use of medications for painful diabetic neuropathy, and baseline pain score. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Patient reported outcomes (global impression of change) were improved in patients treated with LX9211 compared to placebo.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Adverse events were more frequent in the LX9211 treatment arms and at the higher dose, with the most common being dizziness, headache and nausea.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Nearly all adverse events were reported as mild or moderate. There were no drug-related serious adverse events reported in the study.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A full analysis of the results from RELIEF-DPN-1 will be submitted for publication at an upcoming medical conference and in a peer-reviewed journal.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;The results of this study support the translation of a potential new mechanism of action for neuropathic pain and serve as a testament to the strength of Lexicon&#8217;s science,&#8221; said Craig Granowitz, M.D., Ph.D., Lexicon&#8217;s senior vice president and chief medical officer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;Our scientists were the first to identify AAK1 as a novel target with potential for the treatment of neuropathic pain, making an initial discovery in knockout mice, validating that discovery in collaboration with Bristol-Myers Squibb with small molecule inhibition of the target in animal models, and now translating that discovery in this human clinical proof-of-concept study.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This is an important step towards bringing the benefits of our science to patients, in an area where novel targets are rare and there is a tremendous need for new therapies.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LX9211 is a potent, orally delivered, selective small molecule inhibitor of AAK1, which preclinical studies have shown to reduce pain behavior in models of neuropathic pain without affecting opiate pathways.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for the development in diabetic peripheral neuropathic pain.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About the RELIEF-DPN-1 Study</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">RELIEF-DPN-1 is a Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy, safety and pharmacokinetics of LX9211 in the treatment of painful diabetic neuropathy, also referred to as diabetic peripheral neuropathic pain. The study enrolled 319 patients at approximately 40 U.S. clinical sites, evaluating three treatment groups receiving placebo or one of two dosing regimens of LX9211 (an initial dose of 100 mg followed by once-daily doses of 10 mg or an initial dose of 200 mg followed by once-daily doses of 20 mg). The primary efficacy endpoint under evaluation was the change from baseline to week 6 in ADPS, based on the 11-point numerical rating scale.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">results of the study on the primary endpoint showed a reduction from baseline in ADPS of 1.39 points in the low dose arm and 1.27 points in the high dose arm, compared to 0.72 in the placebo arm. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The RELIEF-DPN-1 study is the first of two Phase 2 proof-of-concept studies evaluating LX9211 in neuropathic pain.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">LX9211 is also under evaluation in RELIEF-PHN-1, a study in patients with post-herpetic neuralgia, from which Lexicon is targeting top-line results around the end of the third quarter of 2022.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About LX9211 </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Discovered using Lexicon&#8217;s unique approach to gene science, LX9211 is a potent, orally delivered, selective small molecule inhibitor of adaptor-associated kinase 1 (AAK1). Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain and identified LX9211 and another development candidate in a neuroscience drug discovery alliance with Bristol-Myers Squibb from which Lexicon holds exclusive development and commercialization rights. Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for the development in diabetic peripheral neuropathic pain. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Conference Call and Webcast Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon management will hold a live conference call and webcast on June 30, 2022 at 8&#58;00 am ET &#47; 7&#58;00 am CT to discuss the RELIEF-DPN-1 top-line results.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The dial-in number for the conference call is 888-886-7786 (U.S.&#47;Canada) or 416-764-8658 (international). The conference ID for all callers is 20954316. The live webcast and replay may be accessed by visiting Lexicon&#8217;s website at </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.lexpharma.com&#47;events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. An archived version of the webcast will be available on the website for 14 days.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Lexicon Pharmaceuticals </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives. Through its Genome5000&#8482; program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, diabetes and metabolism and other indications.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For additional information, please visit </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">www.lexpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Safe Harbor Statement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">This press release contains &#8220;forward-looking statements,&#8221; including statements relating to the clinical development of and potential therapeutic and commercial potential of LX9211. In addition, this press release also contains forward looking statements relating to the clinical development of, regulatory filings for and potential therapeutic and commercial potential of sotagliflozin and Lexicon&#8217;s other potential drug candidates, as well as Lexicon&#8217;s financial position and long-term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management&#8217;s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon&#8217;s ability to meet its capital </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon&#8217;s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under &#8220;Risk Factors&#8221; in Lexicon&#8217;s annual report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For Inquiries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mike Kelly</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lexicon Pharmaceuticals, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">mkelly&#64;lexpharma.com</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lxrx-20220629.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7f89d13d-bd55-4120-abc6-81eefc01febb,g:126522bb-f532-4f89-a56b-06c2467ad2f3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20220629" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20220629">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220629_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220629_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.lexpharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lxrx-20220629_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7f89d13d-bd55-4120-abc6-81eefc01febb,g:126522bb-f532-4f89-a56b-06c2467ad2f3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_549a0a6b-13c0-4837-a6a2-c5171b70d822_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_71eb0f6e-5e99-4948-b0b7-74c88aed6b31_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0cc972f7-bb5c-4845-b4d0-11e1e2def591_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_db13f6e1-c468-42c9-b011-53965bd8a536_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9f2be65e-09ee-469c-b6c3-d836bee9114c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_3828cada-9037-4929-b11a-ce90e68b42f3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_1d9c0ffd-8bd2-4d34-bd38-94ca7acca0c5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6f821712-b2b9-48ac-ad03-3c9127327d49_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_727f7307-7c70-4032-891f-ccbf84c6a88f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_87d50953-8fbd-4d30-a552-3c92a07ecde4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_72fac6c5-b3f3-42bb-aaf1-98028814f6a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_64440436-3ea0-4389-9ff8-1309c0ea469f_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_dbd8f5f7-6abd-4c55-ac08-65cc67cbfd88_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c0c283bb-d269-478b-b633-0576983eece2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_aab1f045-7809-49d0-a0a4-d8d413715f18_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_abd4ef45-680f-450f-8dd1-5d4232a4c57a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5fb9ff25-e169-4778-bde6-4e882e12aa2a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bde1b4fe-3ec7-49e0-b094-705e23f20cf8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bd31c739-a675-4318-a71c-774923641bf1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_02fc1f4e-1478-4781-815a-2eae485c2832_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6cb92485-407d-49cb-98b9-08a5798181ac_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_64bda872-b127-440a-9dcd-66ae8c30d083_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lxrx-20220629_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:7f89d13d-bd55-4120-abc6-81eefc01febb,g:126522bb-f532-4f89-a56b-06c2467ad2f3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/Cover" xlink:type="simple" xlink:href="lxrx-20220629.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9cc76fa9-8c3a-4728-994c-c5d7a1e6b119" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_DocumentType_9cc76fa9-8c3a-4728-994c-c5d7a1e6b119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e3a10db9-cfd5-45d0-9a47-6f2983b5a353" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_DocumentPeriodEndDate_e3a10db9-cfd5-45d0-9a47-6f2983b5a353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fbdc08de-4070-4912-bcad-8b736bb21585" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityRegistrantName_fbdc08de-4070-4912-bcad-8b736bb21585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_36e9c5a6-a157-4be9-8e74-468bcb024ef1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityIncorporationStateCountryCode_36e9c5a6-a157-4be9-8e74-468bcb024ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1d6beede-bc14-4b37-9ff7-f26ef4228b79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityFileNumber_1d6beede-bc14-4b37-9ff7-f26ef4228b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9a80efb9-6ec3-4df5-9e51-c549752fb0d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityTaxIdentificationNumber_9a80efb9-6ec3-4df5-9e51-c549752fb0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_67c86964-d60c-49ff-8eeb-68b89ebb0a5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityAddressAddressLine1_67c86964-d60c-49ff-8eeb-68b89ebb0a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f967264a-fb71-4085-8577-f53288af9a53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityAddressCityOrTown_f967264a-fb71-4085-8577-f53288af9a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cf80ab9c-ac4a-439a-984b-f186253b53a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityAddressStateOrProvince_cf80ab9c-ac4a-439a-984b-f186253b53a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_40600445-d032-4bba-80d4-e33fca6c3dbb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityAddressPostalZipCode_40600445-d032-4bba-80d4-e33fca6c3dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_241a286f-f64d-45ad-8d99-e7b47a19e76a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_CityAreaCode_241a286f-f64d-45ad-8d99-e7b47a19e76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1f6da3df-a4de-471b-9226-9b6a82fe3240" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_LocalPhoneNumber_1f6da3df-a4de-471b-9226-9b6a82fe3240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6115c565-d8c3-4eea-97e5-df7b4369e862" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_Security12bTitle_6115c565-d8c3-4eea-97e5-df7b4369e862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a554c3ae-4154-4bba-bf1f-50d6545a95a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_TradingSymbol_a554c3ae-4154-4bba-bf1f-50d6545a95a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_269b8f7b-dd9c-4c4d-876d-f859d8cde878" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_SecurityExchangeName_269b8f7b-dd9c-4c4d-876d-f859d8cde878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_08dec0e5-f670-4db3-9c9a-fdbff8602f0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_WrittenCommunications_08dec0e5-f670-4db3-9c9a-fdbff8602f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_101c6bfe-361f-4037-af3d-8a3025c15905" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_SolicitingMaterial_101c6bfe-361f-4037-af3d-8a3025c15905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_0478f19e-d8e0-4936-9362-deb08134d9e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_PreCommencementTenderOffer_0478f19e-d8e0-4936-9362-deb08134d9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_c756aec5-6f3b-4282-a950-3d3384a40e61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_c756aec5-6f3b-4282-a950-3d3384a40e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6fe3b3fe-e5f1-4b7e-9751-c8a36dabfc3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityEmergingGrowthCompany_6fe3b3fe-e5f1-4b7e-9751-c8a36dabfc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e900281e-7ee0-4af6-875c-b878bd2339ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_EntityCentralIndexKey_e900281e-7ee0-4af6-875c-b878bd2339ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1da7614a-99d2-42a8-9e92-ca6d24a988cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e89f0ae-eae7-4b17-816a-522908adcb94" xlink:to="loc_dei_AmendmentFlag_1da7614a-99d2-42a8-9e92-ca6d24a988cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140270566669584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 29,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd., 11th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>lxrx-20220629_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20220629.xsd" xlink:type="simple"/>
    <context id="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF80L2ZyYWc6NTJiZjNiNmRjM2EwNGNkYWI0ZDRlZjU3MjAxYzRjZGIvdGFibGU6YTFmZTk1MDBlZTU2NDVjZWI3ZGFkNjVkNzI2NzZlMDIvdGFibGVyYW5nZTphMWZlOTUwMGVlNTY0NWNlYjdkYWQ2NWQ3MjY3NmUwMl8wLTEtMS0xLTI4NDM2_b003f9b1-65cc-4e66-be97-dc579ecd1f1c">0001062822</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF80L2ZyYWc6NTJiZjNiNmRjM2EwNGNkYWI0ZDRlZjU3MjAxYzRjZGIvdGFibGU6YTFmZTk1MDBlZTU2NDVjZWI3ZGFkNjVkNzI2NzZlMDIvdGFibGVyYW5nZTphMWZlOTUwMGVlNTY0NWNlYjdkYWQ2NWQ3MjY3NmUwMl8xLTEtMS0xLTI4NDM2_577c79da-866c-42c7-afeb-275fce7c1969">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNzAx_7ca3b16b-b842-465d-bd13-301673a0c408">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8yNjU_d6bbfc79-97d5-4bc7-b2d8-08f7f9c3a11d">2022-06-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk0_14fd1dd3-ea88-49c2-aac1-42e41265cdae">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6MjRjNjZiZTRhMzI5NGQwY2E3Y2I5NDNiNDBmYmE3NzQvdGFibGVyYW5nZToyNGM2NmJlNGEzMjk0ZDBjYTdjYjk0M2I0MGZiYTc3NF8wLTAtMS0xLTI4NDM2_58e24a9a-1d33-48b7-a8c7-3ed0562cb747">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6MjRjNjZiZTRhMzI5NGQwY2E3Y2I5NDNiNDBmYmE3NzQvdGFibGVyYW5nZToyNGM2NmJlNGEzMjk0ZDBjYTdjYjk0M2I0MGZiYTc3NF8wLTEtMS0xLTI4NDM2_3366901e-84f6-48ab-85eb-4aa8e6bc112e">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6MjRjNjZiZTRhMzI5NGQwY2E3Y2I5NDNiNDBmYmE3NzQvdGFibGVyYW5nZToyNGM2NmJlNGEzMjk0ZDBjYTdjYjk0M2I0MGZiYTc3NF8wLTItMS0xLTI4NDM2_ed83d2ad-f35f-4c8f-9ea8-2e86bf8662ed">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjg4_8f86efce-d665-439c-84c8-3f0bd141fcfd">2445 Technology Forest Blvd., 11th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNzAw_03b9f13c-fd6c-4a12-991a-35a18d72968f">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk1_6fc75b76-31c3-4294-9237-f88b684d76c6">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl80MjA_2e8f6787-3d8d-42ef-8f0a-faff555a5f33">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl80Nzk_a059fc45-5a64-4d2c-a414-e6c08dad9438">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjg5_9028f1c3-9661-4144-bec3-e8c057c85fdb">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6NzkzYzljYTJkMTc2NGM4MjljYWZiNGE0MTM0YWY5MWUvdGFibGVyYW5nZTo3OTNjOWNhMmQxNzY0YzgyOWNhZmI0YTQxMzRhZjkxZV8xLTAtMS0xLTI4NDM2_4cf0759b-9924-4aa3-8402-9ca14b20a188">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6NzkzYzljYTJkMTc2NGM4MjljYWZiNGE0MTM0YWY5MWUvdGFibGVyYW5nZTo3OTNjOWNhMmQxNzY0YzgyOWNhZmI0YTQxMzRhZjkxZV8xLTEtMS0xLTI4NDM2_3dd76deb-e45c-4204-8df1-7d548457800d">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGFibGU6NzkzYzljYTJkMTc2NGM4MjljYWZiNGE0MTM0YWY5MWUvdGFibGVyYW5nZTo3OTNjOWNhMmQxNzY0YzgyOWNhZmI0YTQxMzRhZjkxZV8xLTItMS0xLTI4NDM2_14add6c8-b186-44be-b064-67ead65c2b46">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjkw_bd8eb20b-1152-4dd1-85e4-2c4899d04078">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk2_e94743a3-085a-4bc6-abf0-bcb8e0e79416">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk3_3fcaa6cd-b422-4272-aaee-4cc1ff4ebc0d">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjky_2c5c0b1b-8038-4d41-a0fb-d53b6e26b337">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i905661c747154b43bd8d41d10f1014e1_D20220629-20220629"
      id="id3VybDovL2RvY3MudjEvZG9jOjg2ZmFmZTk2OThkZjQwMDc5M2M5MGU1NjVhMjdiNzAwL3NlYzo4NmZhZmU5Njk4ZGY0MDA3OTNjOTBlNTY1YTI3YjcwMF8xL2ZyYWc6Mjk2NzU0ODllZWMwNDU2ODlhMzZmZWNmNjI3ODFmZWIvdGV4dHJlZ2lvbjoyOTY3NTQ4OWVlYzA0NTY4OWEzNmZlY2Y2Mjc4MWZlYl8xNjk5_1650b037-1fcc-48a6-867c-c7905ef6e5ec">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ CF;>5 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " ".9MY4
MYL:65^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " ".9MY4F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (YFWE3\.SX#4@0
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M2P$"% ,4    " ".9MY4)!Z;HJT   #X 0  &@              @ &Z$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ".9MY499!Y
MDAD!  #/ P  $P              @ &?$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  #I$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lxrx-20220629.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lxrx-20220629.htm">lxrx-20220629.htm</File>
    <File>lxrx-20220629.xsd</File>
    <File>lxrx-20220629_lab.xml</File>
    <File>lxrx-20220629_pre.xml</File>
    <File>pressrelease06-29x2022.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20220629.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "lxrx-20220629.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20220629_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20220629_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20220629.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20220629",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220629.htm",
      "contextRef": "i905661c747154b43bd8d41d10f1014e1_D20220629-20220629",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.lexpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220629.htm",
      "contextRef": "i905661c747154b43bd8d41d10f1014e1_D20220629-20220629",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001062822-22-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-22-000030-xbrl.zip
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MF[1.V%>OVZYPN%[;[V<KZ 7;O5Z,G@!02P,$%     @ CF;>5%UDVL] "@
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ML^"JF$5(<9B$"@0JC@&)"04<\@A$1%#*E RYC^P$W3+22(6MT7I-N-X*KZW
MVPCN*O1GH&T8P=LSYB#\ VST2 !MG@=.! <"W$T(ARYP30SOI-239+G^3U<7
M"LV@$'&$DPAP'@B]RI, <"(A0$@AA:5*@M@R*1A&&6E"6$-\N7GA56"]SYFR
M30@F8KLF@YYT#9,([)ER2 1[F.B1!$Q>!TX >P+;%?\^8WOA7Q2L:G:=WR]X
M/I])CGQ= " @2$@!P2+6%0!"(/#C,."2LL /NXJ]X7EL E^#\U;HNLNY2==A
M"3N3<&39=HS?2J3&6)V$V?0TF!B- 6P+T&S@NMI^2.=J71C&">8J#!2 L5*
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M=BY4&F5&>[RE[UFH+1&IQ*0NMT!U\"N)K_&;8^.*Y\(!%O0('W"?55'A89U
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M21-A@@M'6;L8]JY) >V($#)G6UN?OSUCTQN2D+1C[2>$0)+7H#+8VTS:R(G
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MZ):?W)*8OWNQNW.T-C/_\I6OMZTOL;O'P08W_7\WP__QS=M_ U!+ 0(4 Q0
M   ( (YFWE0Y ?U.RQ8  ,J&   1              "  0    !L>')X+3(P
M,C(P-C(Y+FAT;5!+ 0(4 Q0    ( (YFWE0V^G"]:P(  '$'   1
M      "  ?H6  !L>')X+3(P,C(P-C(Y+GAS9%!+ 0(4 Q0    ( (YFWE1=
M9-K/0 H  !A=   5              "  909  !L>')X+3(P,C(P-C(Y7VQA
M8BYX;6Q02P$"% ,4    " ".9MY4Y<(-P:D&  #>,   %0
M@ $')   ;'AR>"TR,#(R,#8R.5]P<F4N>&UL4$L! A0#%     @ CF;>5/9R
MU>D:$   4T<  !H              ( !XRH  '!R97-S<F5L96%S93 V+3(Y
?>#(P,C(N:'1M4$L%!@     %  4 3 $  #4[      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
